科研之友
微信
新浪微博
Facebook
分享链接
摘要
The development of radiopharmaceuticals based on biological molecules has been increasing in the last few years. The high specificity associated with high affinity, especially in tumours site has emerged this class of radiopharmaceuticals as a whole new perspective, for both: therapy and imaging. In this study we develop and evaluate the aptamer anti-MUC1 labelled with Ga-68 and Na-22 as PET radio pharmaceutical for prostate cancer. The results showed that the methodology developed for labelling the aptamer with Ga-68 and Na-22 (separately) was quite efficient and support as a methodology that could be used for cold kit in nuclear medicine daily routine.
- 出版日期2016-11
